

平成 30 (2018) 年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	相崎英樹	C 型肝炎ウイルスの遺伝子構造と抗ウイルス薬の作用機序は		日本医事新報	日本医事新報社	東京	2018	64-65	
2)	芥田憲夫、熊田博光	肝疾患治療薬-B 型・C 型肝炎における抗ウイルス療法・抗炎症療法	堀正二、菅野健太郎、門脇孝、乾賢一、林昌洋	治療薬ハンドブック 2018	(株)じほう	東京	2018	575-580	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M	Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey	Annals of Surgery	in press	doi: 10.1097/SLA.0000000000003192	2019	
2)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, <u>Tanaka J</u>	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic	Journal of Gastroenterology and Hepatology	in press	doi: 10.1111/jgh.14564	2019	
3)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, <u>Tanaka J</u> , Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study	Liver International	39(3)	448-54, doi: 10.1111/liv.13987	2019	
4)	Nagashima S, Yamamoto C, Ko K, Chuon C, Sugiyama A, Ohisa M, Akita T, Katayama K, Yoshihara M, <u>Tanaka J</u>	Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination	Vaccine	37(1)	145-51, doi: 10.1016/j.vaccine.2018.11.019	2019	
5)	Yamamoto C, Ko K, Nagashima S, Harakawa T, Fujii T, Ohisa M, Katayama K, Takahashi K, Okamoto H, <u>Tanaka J</u>	Very low prevalence of anti-HAV in Japan: high potential for future outbreak	Scientific Reports	9(1)	1493, doi: 10.1038/s41598-018-37349-1	2019	
6)	Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, <u>Tanaka J</u> , Chayama K	Levodocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis	Hepatology Communications	22(3)	348-55, doi: 10.1002/hep4.1309	2019	
7)	<u>Tanaka J</u> , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, Satake M	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	Journal of Viral Hepatitis	25(4)	363-72, doi: 10.1111/jvh.12828	2018	
8)	Kaishima T, Akita T, Ohisa M, Sakamune K, Kurisu A, Sugiyama A, Aikata H, Chayama K, <u>Tanaka J</u>	Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan	Hepatology Research	48(7)	509-20, doi: 10.1111/hepr.13053	2018	
9)	Yamasaki K, <u>Tanaka J</u> , Kurisu A, Akita T, Ohisa M, Sakamune K, Ko K, Sugiyama A, Yasaka T, Shirahama S	Natural course of persistent hepatitis B virus infection in HBe antigen-positive and -negative cohorts in Japan based on the Markov model	Journal of Medical Virology	90(12)	1800-13, doi: 10.1002/jmv.25260	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
10)	Toyoda H, Kumada T, Mizuno K, Hiraoka A, Tuji K, Ishikawa T, Akita T, <a href="#">Tanaka J</a>	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias	Liver International	38(i12)	2260-8, doi: 10.1111/liv.13927	2018	
11)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, <a href="#">Tanaka J</a>	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments	Alimentary Pharmacology and Therapeutics	48(6)	664-70, doi: 10.1111/apt.14914	2018	
12)	Tada T, Kumada T, Toyoda H, Ohisa M, Akita T, <a href="#">Tanaka J</a>	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model	Journal of Gastroenterology	53(11)	1196-205, doi: 10.1007/s00535-018-1467-x	2018	
13)	Uchida S, Satake M, Kurisu A, Sugiyama A, Ko K, Akita T, <a href="#">Tanaka J</a>	Incidence Rates of Hepatitis C Virus Infection among Blood Donors in Japan: A Nationwide Retrospective Cohort Study	Transfusion	58(12)	2880-5, doi: 10.1111/trf.14951	2018	
14)	Lingani M, Akita T, Ouoba S, Sanou AM, Sugiyama A, Tarnagda Z, Ohisa M, Tinto H, Mishiro S, <a href="#">Tanaka J</a>	High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies	BMC Public Health	18(1)	551, doi: 10.1186/s12889-018-5432-7	2018	
15)	Hirata F, Ishiyama K, Tanaka Y, Kobayashi T, Hashimoto M, Saeki Y, Ishida N, Taguchi K, <a href="#">Tanaka J</a> , Arihiro K, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)	Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis	Annals of Gastroenterological Surgery	2(5)	383-93, doi: 10.1002/ags3.12195	2018	
16)	Matsumoto C, Shinohara N, Furuta RA, Tanishige N, Shimojima M, Matsubayashi K, Nagai T, Tsubaki K, <a href="#">Satake M</a> .	Investigation of antibody to severe fever with thrombocytopenia syndrome virus (SFTSV) in blood samples donated in a SFTS-endemic area in Japan.	Vox Sang	113	297-299	2018	
17)	Furui Y, Yamagishi N, Morioka I, Taira R, Nishida K, Ohyama S, Matsumoto H, Nakamachi Y, Hasegawa T, Matsubayashi K, Nagai T, <a href="#">Satake M</a> .	Sequence analyses of variable cytomegalovirus genes for distinction between breast milk- and transfusion-transmitted infections in very-low-birth-weight infants.	Transfusion	58	2894-2902	2018	
18)	Uchida S, <a href="#">Satake M</a> , Kurisu A, Sugiyama A, Ko K, Akita T, <a href="#">Tanaka J</a>	Incidence rates of hepatitis C virus infection among blood donors in Japan: a nationwide retrospective cohort study.	Transfusion	58	2880-2885	2018	○
19)	<a href="#">Tanaka J</a> , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, <a href="#">Satake M</a> .	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	J Viral Hepat	25	363-372	2018	○
20)	Fukano K, Tsukuda S, Oshima M, Suzuki R, <a href="#">Aizaki H</a> , Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.	Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.	Front Microbiol	9		2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
21)	Takeuchi JS, Fukano K, Iwamoto M, Tsukuda S, Suzuki R, <u>Aizaki H</u> , Muramatsu M, Wakita T, Sureau C, Watashi K.	A Single Adaptive Mutation in Sodium Taurocholate Cotransporting Polypeptide Induced by Hepadnaviruses Determines Virus Species Specificity.	J Virol.		01432-18	2018	
22)	Ohashi H, Nishioka K, Nakajima S, Kim S, Suzuki R, <u>Aizaki H</u> , Fukasawa M, Kamisuki S, Sugawara F, Ohtani N, Muramatsu M, Wakita T, Watashi K.	The aryl hydrocarbon receptor-cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly.	J Biol Chem.	293	19559-19571	2018	
23)	Shirasago Y, Fukazawa H, <u>Aizaki H</u> , Suzuki T, Suzuki T, Sugiyama K, Wakita T, Hanada K, Abe R, Fukasawa M.	Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells.	J Gen Virol.	99	1407-1417	2018	
24)	Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, Ohki M, Ryo A, Park SY, Suzuki R, <u>Aizaki H</u> , Muramatsu M, Sureau C, Wakita T, Matano T, Watashi K.	A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.	Biochem Biophys Res Commun.	22	374-379	2018	
25)	Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, <u>Aizaki H</u> , Ohtani N, Sureau C, Wakita T, Osada H, Watashi K.	Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.	Sci Rep.	8		2018	
26)	Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K	Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride	Hepatology Research	48(1)	45-50	2018	○
27)	Akuta N, Toyoda J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.	Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/aunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection	J Gastroenterol	53(9)	1089-1097	2018	○
28)	<u>Akuta N</u> , Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	The complex association of virus-and host-related factors with HCC rate following HCV clearance.	J Clin Microbiol		doi:10.1128/JCM.01463-18	2018	○
29)	Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, <u>Akuta N</u> , Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H	No-touch ablation in HCC has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.	Hepatology Res		doi:10.1111/hepr.13254	2018	
30)	Suzuki F, Hosaka T, Suzuki Y, Sezaki H, <u>Akuta N</u> , Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.	J Gastroenterol		doi:10.1007/s00535-018-1502-y	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
31)	Takeuchi Y, <u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.	Hepatol Res		doi:10.1111/hepr.13242	2018	
32)	<u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antiviral regimens.	J Med Virol		doi:10.1002/jmv.25278	2018	○
33)	Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, <u>Akuta N</u> , Ito K, Kawamura M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.	Hepatol Res		doi:10.1111/hepr.13226	2018	
34)	<u>Akuta N</u> , Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.	J Med Virol	90(10)	1586-1592	2018	
35)	Kuwano T, <u>Akuta N</u> , Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H	A patient with HCV infection and a sustained virological response to direct-acting antiviral treatment who developed inclusion body myositis.	Intern Med	57(17)	2511-2515	2018	
36)	<u>Akuta N</u> , Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K	Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.	Hepatol Res	48(10)	810-813	2018	
37)	Ogata F, <u>Akuta N</u> , Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H	Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.	J Med Virol	90(6)	1087-1093	2018	○
38)	Ohya K, <u>Akuta N</u> , Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.	J Med Virol	90(5)	919-925	2018	○
39)	Ohya K, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kinowaki K, Fujii T, Kondo F, Kumada H.	Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases.	Hepatol Res		doi:10.1111/hepr.13295	2018	
40)	Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, <u>Akuta N</u> , Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.	Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.	Liver Cancer	7(4)	323-334	2018	
41)	<u>Akuta N</u> , Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.	BMC Gastroenterol	18(1)	165	2018	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
42)	Ogasawara N, Kobayashi M, <u>Akuta N</u> , Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.	J Med Virol	90(2)	313-319	2018	○
43)	小林万利子、芥田憲夫、鈴木文孝、瀬崎ひとみ、鈴木義之、保坂哲也、小林正宏、斎藤聡、川村祐介、荒瀬康司、池田健次、熊田博光	HCV genotype1 または 2 以外の C 型慢性肝疾患における serological group の検討	肝臓	59 巻 8 号	437-438	2018	
44)	Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y1 Tomiyama Y, Kuribayashi F, <u>Torimura T</u> , Hino K.	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.	Cellular and Molecular Gastroenterology and Hepatology	7	115-134	2019	
45)	Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, <u>Torimura T</u> .	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD.	Scientific reports	8	10434(p age.1-13).	2018	○
46)	Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, <u>Torimura T</u> .	Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.	Oncology			2018	
47)	Kawaguchi T, Nakano D, Oriishi T, <u>Torimura T</u> .	Effects of isomaltulose on insulin resistance and metabolites in patients with nonalcoholic fatty liver disease: A metabolomic analysis.	Molecular medicine reports	18	2033-2042	2018	
48)	Kawaguchi T, Nakano D, Koga H, <u>Torimura T</u> .	Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model.	Liver Cancer	in press		2018	
49)	Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E, Yamada M, Sugimoto M, Hayashi S, Goshima N, Yoshiyama T, Otsuka T, Nozoe R, Nagamatsu A, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H1, Koga H, Miura H, Shiba N, <u>Torimura T</u> .	Effects of In-Hospital Exercise on Sarcopenia in Hepatoma Patients Who Underwent Transcatheter Arterial Chemoembolization.	Journal of Gastroenterology and hepatology	in press		2018	
50)	Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, <u>Torimura T</u> , Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group.	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.	Journal of Gastroenterology	53	281-290	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
51)	Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, <u>Torimura T</u> , Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.	Journal of gastroenterology	in press		2018	
52)	Takahashi A, Arinaga-Hino T, Ohira H, Abe K, <u>Torimura T</u> , Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H.	Non-alcoholic fatty liver disease in patients with autoimmune hepatitis.	JGH open : an open access journal of gastroenterology and hepatology	2	54-58	2018	
53)	Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, <u>Torimura T</u> , Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.	An analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan.	Hepatology research : the official journal of the Japan Society of Hepatology	in press		2018	
54)	Kawaguchi T, Inokuchi T, Honma T, Itano S, Kawasaki E, Inada C, Aoki T, Tsumura N, Araki A, Mukae T, <u>Torimura T</u> .	Factors Associated with Advanced Hepatic Fibrosis in Patients with Various Internal Diseases: A Multicenter Community-based Survey.	Hepatology Research	48	882-892	2018	
55)	Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, <u>Torimura T</u> , Saibara T, Kawaguchi A, Nakajima A, Eguchi Y; Japan Study Group for NAFLD (JSG-NAFLD).	Prevalence of pruritus in patients with chronic liver disease: a multicenter study.	Hepatology Research	48	E252-E262	2018	
56)	Arinaga-Hino T, Ide T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Nakamura T, Kawaguchi T, Koga H, Yonemoto K, <u>Torimura T</u> ; Kurume Autoimmune Hepatitis Study Group	Risk of malignancies in autoimmune hepatitis type 1 patients with a long-term follow-up in Japan.	Hepatology Research	48	E222-E231	2018	
57)	Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Guha IN, Kawaguchi T, <u>Torimura T</u> , McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J.	ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis.	Hepatology	in press		2018	
58)	Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, Sun X, Lu Y, Zhou Q, Shi W, <u>Torimura T</u> , Nie G, Li Q, Cao Y.	Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.	Cell metabolism	28	104-117	2018	
59)	Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T, Tanaka T, Kakuma T, Yano H, <u>Torimura T</u> .	High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.	Cancer science	109	2801-2810	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Shota Okamoto, <u>Kazumi Yamasaki</u> , Atsumasa Komori, Seigo Abiru, Shinya Nagaoka, kira Saeki, Satoru Hashimoto, Shigemune Bekki, Hiroaki Okamoto, Hiroshi Yatsushashi	Dynamics of hepatitis B virus serum markers in an acute hepatitis B patient in the incubation phase	Clinical Journal of Gastroenterology		<a href="https://doi.org/10.1007/s12328-018-0925-6">https://doi.org/10.1007/s12328-018-0925-6</a>	2019	
61)	<u>Kazumi Yamasaki</u> , <u>Junko Tanaka</u> , <u>Akemi Kurisu</u> , <u>Tomoyuki Akita</u> , <u>Masayuki Ohisa</u> , <u>Kazuaki Sakamune</u> , <u>Ko Ko</u> , <u>Aya Sugiyama</u> , Takahiro Yasaka, Satoshi Shirahama	Natural course of persistent hepatitis B virus infection in hepatitis B e antigen-positive and hepatitis B e antigen-negative cohorts in Japan based on the Markov mode	Journal of Medical Virology	Volume 90, Issue 12	1785-1887	2018	○
62)	<u>Hino K</u> , Nishina S, Sasaki K, Hara Y.	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection.	Free Radic Biol Med	in press		2018	
63)	Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, <u>Hino K</u>	Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice.	Cell Mol Gastroenterol Hepatol	7	115-34	2018	○
64)	Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, <u>Hino K</u>	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.	Hepatol Res	48	521-8	2018	○
65)	Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, <u>Hino K</u> , Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, Silius study group	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.	Lancet Gastroenterol Hepatol	3	424-32	2018	○
66)	Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, <u>Hino K</u> , Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease.	Hepatol Commun	2	58-68	2018	○
67)	Sawai H, Nishida N, Khor SS, Honda M, Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, Koike K, Kondo Y, Yatsushashi H, Nagaoka S, Taketomi A, Fukai K, Kurosaki M, Izumi N, Kang JH, Murata K, <u>Hino K</u> , Nishina S, Matsumoto A, Tanaka E, Sakamoto N, Ogawa K, Yamamoto K, Tamori A, Yokosuka O, Kanda T, Sakaida I, Itoh Y, Eguchi Y, Oeda S, Mochida S, Yuen MF, Seto WK, Poovorawan Y, Posuwan Y, Mizokami M, Tokunaga K	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma.	Sci Rep	8	7958	2018	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
68)	Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.	J Gastroenterol	53	247-57	2018	○
69)	<u>Miyasaka A</u> , Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanebe D, Hoshino T, Sawara K, Takikawa Y	The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C genotype 1.	Intern Med.	57	2807-2812	2018	○
70)	Yoshida Y, Yonezawa M, Okamoto T, Fujiwara Y, Suzuki A, Suzuki Y, Endo K, Kakisaka K, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Takikawa Y	Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.	Clin J Gastroenterol.			2018	○
71)	Murai K, <u>Shimakami T</u> , Welsch C, Shirasaki T, Liu F, Kitabayashi J, Tanaka S, Funaki M, Omura H, Nishikawa T, Suminyadorj A, Honda M, Kaneko S.	Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in Genotype 1a Hepatitis C Virus. Antimicrob Agents Chemother	Antimicrob Agents Chemother	62	e02601-17	2018	○
72)	Shirasaki T, Honda M, Yamashita T, Nio K, <u>Shimakami T</u> , Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S.	The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication	Sci Rep	8	13143	2018	○
73)	Miyazaki T, Nagasaka H, Komatsu H, Ayano Inui A, Morioka I, Tsukahara H, Kaji S, Hirayama S, Miida T, Kondou H, Ihara K, Yagi M, Kizaki Z, Bessho K, Kodama T, Iijima K, Yorifuji T, <u>Matsuzaki Y</u> , Honda A	Serum amino acid profiling in citrin-deficient children exhibiting normal liver function during the apparently healthy period	JIMD Rep	43	53-61	2019	
74)	Ra SG, TMiyazaki T, Kojima R, Komine S, Ishikura K, Kawanaka K, Honda A, <u>Matsuzaki Y</u> , Ohmori H	Effect of BCAA supplement timing on exercise-induced muscle soreness and damage: A pilot placebo-controlled double-blind study	J Sports Med Phys Fitness	58(11)	1582-1591	2018	
75)	Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara S, Kohijima M, Nakamuta M, <u>Matsuzaki Y</u>	Difference of serum 4 $\beta$ -hydroxycholesterol levels of patients with chronic HCV infection: A possible impact on the efficacy and safety of IFN-free treatment	Intern Med	57(9)	1219-1227	2018	
76)	Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Hirayama T, Miyazaki T, Saito Y, Ikegami T, <u>Matsuzaki Y</u>	Detection of gut dysbiosis due to reduced clostridium subcluster IXVa using the fecal or serum bile acid profile	Inflamm Bowel Dis	24(5)	1035-1044	2018	
77)	Iwamoto J, Murakami M, Konishi N, Monma T, Ueda H, Yara S, Hirayama T, Ikegami T, Honda A, <u>Matsuzaki Y</u>	Effects of the concomitant use of low-dose clarithromycin with an anti-TNF $\alpha$ antibody in a patient with intestinal bechet disease	Intern Med	57(3)	339-342	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
78)	Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K	Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema	J Gastroenterol Hepatol	33(6)	1256-1263	2018	
79)	Asahina Y, Itoh Y, Ueno Y, <u>Matsuzaki Y</u> , Takikawa Y, Yatsuhashi H, Genda T, Ikeda F, Matsuda T, Dvory-Sobol H, Jiang D, Massetto B, Osinusi AO, Brainard DM, McHutchison JG, Kawada N, Enomoto N	Ledipasvir-Sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection	Liver International	38(9)	1552-1561	2018	
80)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease	Hepatol Res	48(7)	549-555	2018	
81)	Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, Kikuchi K, Yasunaka T, Takaki A, Ueno Y, Honda A, <u>Matsuzaki Y</u> , Takikawa H	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis	Sci Rep	8(1)	12542	2018	
82)	Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, <u>Matsuzaki Y</u> , Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG)	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study	J Gastroenterol	53(10)	1151-1158	2018	
83)	Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, <u>Matsuzaki Y</u> , Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study	Hepatol Res		[Epub ahead of print]	2018	
84)	Miyazaki T, Honda A, Ikegami T, Iida T, <u>Matsuzaki Y</u>	Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model	J Clin Biochem Nutr		[Epub ahead of print]	2018	
85)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, Ikegami T, <u>Matsuzaki Y</u> , Honda A	Influences of taurine deficiency on bile acids of the bile in the cat model	Adv Exp Med Biol		(in press)	2018	
86)	Suda G, Furusyo N, <u>Toyoda H</u> , Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamasaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N.	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.	Journal of Gastroenterology	53	119-128	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Kawasaki H, Hiasa Y, Michitaka K.	erwent radiofrequency ablation: usefulness of albumin-bilirubin grade.	Hepatology Research	48	E61-E67	2018	
88)	Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouse K, <u>Toyoda H</u> , Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yomago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K.	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.	Journal of Gastroenterology and Hepatology	34	436-441	2019	
89)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K.	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post-hoc analysis of a multicenter study.	Journal of Gastroenterology and Hepatology	34	364-369	2019	
90)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, <u>Toyoda H</u> , Kumada T, Goto H, Hirooka Y.	Utility and limitations of non-invasive fibrosis markers for predicting prognosis in biopsy-proven Japanese NAFLD patients.	Journal of Gastroenterology and Hepatology	34	207-214	2019	
91)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K.	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis.	Hepatology Research	49	111-117	2019	
92)	Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Nakagawa-Iwashita A, Kondo C, Mikami S, Asano T, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy of direct-acting antivirals treatment in patients with compensated liver cirrhosis: a multicenter study.	Hepatology Research	49	125-135	2019	
93)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Akita Y, Tanaka J, Johnson PJ.	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study.	Liver International	39	448-454	2019	○
94)	Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Sone Y, Oguri T, Kamiyama N.	Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction.	American Journal of Roentgenology	212	332-341	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
95)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouse K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K.	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions – multicenter analysis.	Cancer Medicine	8	137-146	2019	
96)	Kariyama K, Nouse K, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M.	Utility of FIB-4-T as a prognostic factor for hepatocellular carcinoma.	Cancers (Basel)	11	E203	2019	
97)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K.	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.	Hepatology Research		in press		
98)	Tada T, Kumada T, <u>Toyoda H</u> , Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.	Impact of ALBI grade on survival in patients with HCC who received sorafenib: an analysis using time-dependent ROC.	Journal of Gastroenterology and Hepatology		in press		○
99)	Nakashima M, <u>Toyoda H</u> , Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T.	Influence of renal dysfunction on dose reduction and virological efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection.	Hepatology Research		in press		
100)	Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VWS, Cheung R, Zhu Q, Nguyen MH.	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis of 237 studies and 13,044,518 individuals from 16 countries/regions.	Lancet Gastroenterology and Hepatology		in press		
101)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.	Alimentary Pharmacology and Therapeutics		in press		
102)	Takaguchi K, <u>Toyoda H</u> , Tsutui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.	Real-world virological efficacy and safety of daclatasvir/asunaprevir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.	Journal of Gastroenterology		in press		

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
103)	Chuma M, <u>Toyoda H</u> , Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Takana K, Maeda S, Sakamoto N.	Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.	Hepatology Research		in press		
104)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K.	Imaging basis of AFP and WFA+M2BP as indicators of the risk of HCC after SVR.	Journal of Hepatology	68	606-607	2018	○
105)	<u>Toyoda H</u> , Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Nostumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H.	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.	Hepatology	67	505-513	2018	
106)	Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Akita T, Tanaka J.	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.	Journal of Gastroenterology and Hepatology	33	918-925	2018	○
107)	Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, <u>Toyoda H</u> , Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment or genotype 3 infection.	Journal of Gastroenterology	53	566-575	2018	
108)	<u>Toyoda H</u> , Kumada T, Tada T, Yama T, Mizuno K.	Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy.	Journal of Gastroenterology and Hepatology	33	1264-1270	2018	
109)	Shinkai N, Nojima M, Iio E, Matsunami K, <u>Toyoda H</u> , Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y.	High levels of Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.	Journal of Gastroenterology	53	883-889	2018	
110)	Tada T, Kumada T, <u>Toyoda H</u> , Saibara T, Ono M, Kage M.	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.	Biomarkers	23	328-334	2018	
111)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease.	Hepatology Research	48	549-555	2018	
112)	Tada T, Kumada T, <u>Toyoda H</u> , Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J.	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy.	Alimentary Pharmacology and Therapeutics	47	1012-1022	2018	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
113)	Okubo T, Atsukawa M, Tsubota A, <u>Toyoda H</u> , Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.	Hepatology International	12	133-142	2018	
114)	Tada T, Kumada T, <u>Toyoda H</u> , Ohisa M, Akita T, Tanaka J.	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model.	Journal of Gastroenterology	53	1196-1205	2018	○
115)	Yasuda S, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, <u>Toyoda H</u> , Kumada T, Hirooka Y, Goto H.	Substitutions in interferon sensitivity determining region and hepatocarcinogenesis after hepatitis C virus eradication.	Journal of Gastroenterology and Hepatology	33	1904-1911	2018	
116)	<u>Toyoda H</u> , Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T.	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.	Journal of Gastroenterology	53	1276-1284	2018	
117)	Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, <u>Toyoda H</u> , Zhou MT.	A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection.	Clinica Chimica Acta	485	187-194	2018	
118)	Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, <u>Toyoda H</u> , Kumada T, Hattori M, Katano Y, Goto H.	Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.	Journal of Viral Hepatitis	25	1446-1451	2018	
119)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J.	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.	Alimentary Pharmacology and Therapeutics	48	664-670	2018	○
120)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J.	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: a novel approach for the adjustment of lead time bias.	Liver International	38	2260-2268	2018	○
121)	Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, <u>Toyoda H</u> , Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.	Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.	Hepatology International	12	356-367	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
122)	Chan AWH, Zhong J, Berhane S, <u>Toyoda H</u> , Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, Garcia-Finana M, Kudo M, Kumada T, Roayaie S, Johnson PJ.	Prediction of early recurrence after surgical resection of hepatocellular carcinoma: an international collaborative study.	Journal of Hepatology	69	1284-1293	2018	
123)	Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, <u>Toyoda H</u> , Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.	Circulating let-7 levels in serum correlates with the severity of hepatic fibrosis in chronic hepatitis C.	Open Forum Infectious Diseases	5	ofy268	2018	
124)	Nobuhiro Ando, Keisuke Iwata, Kenji Yamazaki, Shogo Shimizu, <u>Junichi Sugihara</u> , Masaki Katayama, Hitoshi Iwata, Takuji Iwashita, Masahito Shimizu	A case of liver hilar tuberculous lymphadenitis complicated by biliary stricture diagnosed by endoscopic ultrasound-guided fine-needle aspiration	Clinical J of Gastroenterology	12		2018	
125)	清水省吾、山下晃司、杉原潤一、中野達徳、高橋雅春、長嶋茂雄、岡本宏明	化学療法の経過中に血小板減少を伴う E 型肝炎を発症し、肝炎治癒後の Nivolumab 治療により重篤な血小板減少症を併発した進行胃癌の 1 例	肝臓	59(9)	497 - 500	2018	
126)	山崎健路、山下晃司、九嶋亮治、岩田仁、中西孝之、永野淳二、安藤暢洋、杉原潤一、清水雅仁	黒色便を契機に診断された胃ラントラン沈着症の 1 例	Gastroenterological Endoscopy	60	215-222	2018	
127)	中野達徳、岡野 宏、西垣洋一、鈴木祐介、富田栄一、小林真、山脇 真、清水省吾、山下晃司、杉原潤一、高橋和明、新井雅裕、高橋雅春、長嶋茂雄、岡本宏明	孤発例でありながら、HEV 遺伝子解析により感染源が同一と推測された中部地方発生の E 型肝炎の 3 組 6 症例	肝臓	59(12)	700-703	2018	

